Drugs / IgPro10
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04138485 | Dec 2019 → Sep 2020 | diffuse cutaneous systemic sclerosis | CSL Behring | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04137224 | Sep 2019 → May 2022 | diffuse cutaneous systemic sclerosis | CSL Behring | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00322556 | Nov 2005 → Apr 2008 | common variable immunodeficiency, selective IgG immunodeficiency | CSL Behring | Completed | No outcome recorded |
| Phase 3 | NCT00168025 | Sep 2004 → Mar 2006 | common variable immunodeficiency, selective IgG immunodeficiency | CSL Behring | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03684018 | Feb 2019 → Dec 2029 expected | chronic inflammatory demyelinating polyradiculoneuropathy | CSL Behring | Recruiting | No outcome recorded |
| Phase 4 | NCT01390649 | Nov 2011 → Sep 2014 | autoimmune thrombocytopenic purpura | CSL Behring | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01545076 Background | Mar 2012 → Sep 2016 | polyneuropathy, inflammatory demyelinating, chronic, polyradiculoneuropathy | CSL Behring | Completed | Met primary |
Press releases naming this drug 11 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IgPro10 | “A Multicenter Study on the Efficacy, Safety and Pharmacokinetics of IgPro10 in Patients With Primary Immunodeficiency (PID)” NCT00168025 ↗6“Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)” NCT00322556 ↗ |
| Known as | Privigen | “10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue...” NCT01545076 ↗1“IgPro10 (Intravenous Immunoglobulin, Privigen®)” NCT04137224 ↗ |
| Modality | Protein / enzyme biologic | “a novel, 10% liquid formulation of intravenous immunoglobulin” PMID 18814020 ↗ Sep 2008 |
| Route | Intravenous | “for intravenous administration” PMID 20217199 ↗ Mar 2010 |